Immunotherapy for colorectal cancer.
Immunologic approaches to therapy for colorectal cancer have evolved substantially. In the past, patients were treated with nonspecific immune stimulants such as bacillus Calmette-Guérin (BCG). The current focus lies in targeting tumor-associated antigens. This is done either through passive immune therapy, with antibodies targeted directly to tumor cells, or by active immune therapy through vaccination with tumor cells, tumor cell lysates, peptides, carbohydrates, gene constructs encoding proteins, or anti-idiotype antibodies that mimic tumor-associated antigens. These different approaches to immunotherapy are reviewed.
Foon
K A
KA
The Barrett Cancer Center, University of Cincinnati, 234 Goodman Avenue, Cincinnati, OH 45267-0502, USA. kenneth.foon@uc.edu
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002241:Carbohydrates; D002272:Carcinoembryonic Antigen / Q000276:immunology; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000379:methods*; D009077:Mucins; D010455:Peptides; D011868:Radioisotopes / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D002241:Carbohydrates; D002272:Carcinoembryonic Antigen; D009077:Mucins; D010455:Peptides; D011868:Radioisotopes